The Overview of Japanese Long Listed Drug Market ver.2017
SKU:
$980.00
$980.00
per item
Japan used to be the only paradise for long listed drugs, as there were no significant drops even when relevant generics launched.
Physicians in Japan who possess the ability to write prescriptions hold a deeply rooted faith in new drugs. Moreover, it used to benefit medical institutions and pharmacies to give preferential treatment to new drugs that conventionally have large profit margins. Furthermore, under the NHI system, most patients pay only 30% out of pocket charge for all medical services, including drugs. It doesn’t bring much difference to people, whether a new drug or a generic is prescribed.
On the other hand, the government in recent years has begun serious efforts to promote the use of generics in order to control medical costs that continue to grow year after year. Revision of medical treatment fees, dispensing fees, etc. has led to the emergence of steady results.
Then, the share of generics in the prescription drugs market has been dramatically increasing in terms of both volume and value. The recent volume share was 60.1% in the 2nd quarter in 2016.
In 2014, NHI price revision has introduced progressive price cuts for off-patent originator brands when generic substitution rates are below 60%, which was raised the bar to 70% in 2016. The government is now thinking about expanding the price cut ratio further.
New drug companies will face with the significant pressure to focus on developing “real” new drugs, giving up non-core businesses including long listed drugs. We can expect more alliance or buyout cases related to long listed drugs in the future.
On the other hand, it would be a good opportunity for generic companies, new players in Japan, especially new entrants from abroad, and other business sectors such as retailers, CMO, and CRO, who have been diligently watching the opportunity to enter into “manufacturer” side, even investment fund groups who see the long listed drugs as promising cash makers in the short term.
Physicians in Japan who possess the ability to write prescriptions hold a deeply rooted faith in new drugs. Moreover, it used to benefit medical institutions and pharmacies to give preferential treatment to new drugs that conventionally have large profit margins. Furthermore, under the NHI system, most patients pay only 30% out of pocket charge for all medical services, including drugs. It doesn’t bring much difference to people, whether a new drug or a generic is prescribed.
On the other hand, the government in recent years has begun serious efforts to promote the use of generics in order to control medical costs that continue to grow year after year. Revision of medical treatment fees, dispensing fees, etc. has led to the emergence of steady results.
Then, the share of generics in the prescription drugs market has been dramatically increasing in terms of both volume and value. The recent volume share was 60.1% in the 2nd quarter in 2016.
In 2014, NHI price revision has introduced progressive price cuts for off-patent originator brands when generic substitution rates are below 60%, which was raised the bar to 70% in 2016. The government is now thinking about expanding the price cut ratio further.
New drug companies will face with the significant pressure to focus on developing “real” new drugs, giving up non-core businesses including long listed drugs. We can expect more alliance or buyout cases related to long listed drugs in the future.
On the other hand, it would be a good opportunity for generic companies, new players in Japan, especially new entrants from abroad, and other business sectors such as retailers, CMO, and CRO, who have been diligently watching the opportunity to enter into “manufacturer” side, even investment fund groups who see the long listed drugs as promising cash makers in the short term.
